Lonza Bioscience's sales for the half year ended June 30 rose
7.0% to CHF 107 million ($93.5 million) (see page 12). Cell Discovery
and Molecular Biology sales were slightly below target levels due to
greater competition in Europe.
COPYRIGHT 2008 Strategic Directions International
Inc. (SDI) Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2008 Gale, Cengage Learning. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.